Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α

A study from China found that the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) can adversely affect interferon-α treatment in patients with BCR/ABL-negative MPNs, causing poor clinical response and increasing adverse events.

 Medical Science Monitor

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.